单独使用贝瓦西祖马布和结合伊利诺特干治疗复发性质母细胞瘤

Henry S Friedman1, Michael D Prados1, Patrick Y Wen1

  • 1From the Brain Tumor Center, Duke University, Durham, NC; Department of Neurosurgery, University of California, San Francisco, San Francisco; Genetech Inc, South San Francisco; and Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles, CA; Department of Neurology, Brigham and Women's Hospital and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA; Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI; Department of Neurology, University of Virginia, Charlottesville, VA; Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Neuro-Oncology, M. D. Anderson Cancer Center, Houston, TX; Division of Neurology, Evanston Northwestern Healthcare, Evanston, IL; Department of Neurology, University of Chicago, Chicago, IL; and University of Utah Hospital, Salt Lake City, UT.

概括

贝瓦西祖马布 (bevacizumab),有或没有 irinotekan,在复发性质母细胞瘤患者中表现出活性. 组合疗法耐受良好,并证明改善了无进展生存率.